Acrivon Therapeutics reported a net loss of $18.2 million for the quarter ended September 30, 2025, a reduction from the $22.4 million loss recorded in the same period a year earlier. Research and development spending fell to $13.6 million, down from $18.9 million, while general and administrative costs were $6.0 million, slightly lower than the $6.3 million reported in 2024. Cash, cash equivalents and investments stood at $134.4 million as of September 30, 2025, giving the company a runway that extends into the second quarter of 2027.
The narrowing of the net loss reflects disciplined cost management and a shift in the company’s clinical focus. Fewer scheduled milestones in the quarter, combined with a prioritization of the endometrial‑cancer program for ACR‑368, reduced R&D outlays. General and administrative expenses remained stable, indicating that overhead costs were kept in line with the company’s operating scale.
Cash reserves have slipped from $147.6 million at the end of Q2 2025, but the current balance still supports ongoing development through mid‑2027. The company’s cash runway is a key buffer for a clinical‑stage biopharma, allowing it to pursue pipeline milestones without immediate financing pressure.
Acrivon’s pipeline continues to advance. ACR‑368, a CHK1/CHK2 inhibitor, is in a registrational‑intent Phase 2b trial for endometrial cancer, and its companion diagnostic, the ACR‑368 OncoSignature test, has received FDA Breakthrough Device designation. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 studies and has shown early clinical activity, including tumor shrinkage and a confirmed partial response. Both assets are supported by the company’s proprietary Generative Phosphoproteomics AP3 platform, which informs drug design and patient selection.
Management emphasized the company’s disciplined approach to development. “Our team continues to efficiently advance our AP3‑enabled pipeline of targeted agents, maintaining strong momentum over the past quarter,” said CEO Peter Blume‑Jensen. The statement underscores confidence in the company’s cost controls and the strategic focus on high‑potential programs.
The combination of a narrowed loss, a robust cash position, and tangible clinical progress positions Acrivon to sustain operations and pursue further development through 2027. The company’s focus on precision oncology, underpinned by the AP3 platform, remains a differentiator in a competitive market, and the current financial footing provides the flexibility to capitalize on upcoming data releases and potential regulatory milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.